We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Response to Pederson et al. and Chlebowski et al.
- Authors
Cold, Søren; Cold, Frederik; Jensen, Maj-Britt; Cronin-Fenton, Deirdre; Christiansen, Peer; Ejlertsen, Bent
- Abstract
The study included patients with low-, intermediate-, and high-risk tumors with 67% of the patients with a tumor size no larger than 2 cm, 57% of the patients with node-negative disease, and an anticipated relatively low number of HER2-positive and/or HER2-enriched patients (all having 10%-100% estrogen receptor expression) ([3]). The strengths of our study include the treatment of breast cancer patients according to national guidelines ([5]). We thank Pederson and colleagues ([1]) and Chlebowski and colleagues ([2]) for their thoughtful correspondence related to our study.
- Subjects
HORMONE receptor positive breast cancer; HER2 positive breast cancer; PATIENT compliance
- Publication
JNCI: Journal of the National Cancer Institute, 2023, Vol 115, Issue 2, p229
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djac214